Global IPO Market Achieves Six-Year High Amid Pandemic
The global IPO market hit a six-year record in 2020 as pandemic-induced volatility was followed by a swift rebound in the second half. Global IPOs raised more than $220 billion in 2020, up 31% from 2019 and well above the $151 billion ten-year median. Despite...read more
The IPO Market Has the Best of Times in the Worst of Times 2020 was a year to forget for many people, but it was unforgettable for IPO investors who benefitted from both the number of IPOs and their outsized average returns. While the COVID-19 pandemic sent global markets into a nosedive in March, the IPO window...read more
Less than nine months after Covid-19 became an unwelcome household word, the virus may be close to being vanquished. A number of biotech IPOs are key players in vaccine development. Most prominent is headline grabber Moderna (MRNA), which went public in December 2018. However, BioNTech (BNTX), an October 2019 IPO, and Pfizer may be first to get FDA approval. Vir...read more
Four IPOs and six SPACs entered the public markets this past week led by CureVac (CVAC), which posted the largest first-day pop for a US IPO since 2005. German biotech CureVac (CVAC) raised $213 million at a $2.8 billion market cap and soared 249% on its first day of trading. With a portfolio of mRNA-based therapies and vaccines, the company developing a...read more
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Renaissance Capital's 2020 Global IPO Market Recap
Global IPO Market Achieves Six-Year High Amid Pandemic The global IPO market hit a six-year record in 2020 as pandemic-induced volatility was followed by a swift rebound in the second half. Global IPOs raised more than $220 billion in 2020, up 31% from 2019 and well above the $151 billion ten-year median. Despite...read more
Updated: Renaissance Capital's 2020 US IPO Market Review
The IPO Market Has the Best of Times in the Worst of Times 2020 was a year to forget for many people, but it was unforgettable for IPO investors who benefitted from both the number of IPOs and their outsized average returns. While the COVID-19 pandemic sent global markets into a nosedive in March, the IPO window...read more
Biotech IPOs close to beating Covid-19
Less than nine months after Covid-19 became an unwelcome household word, the virus may be close to being vanquished. A number of biotech IPOs are key players in vaccine development. Most prominent is headline grabber Moderna (MRNA), which went public in December 2018. However, BioNTech (BNTX), an October 2019 IPO, and Pfizer may be first to get FDA approval. Vir...read more
US IPO Weekly Recap: Coronavirus vaccine developer CureVac pops 249% in a 4 IPO week
Four IPOs and six SPACs entered the public markets this past week led by CureVac (CVAC), which posted the largest first-day pop for a US IPO since 2005. German biotech CureVac (CVAC) raised $213 million at a $2.8 billion market cap and soared 249% on its first day of trading. With a portfolio of mRNA-based therapies and vaccines, the company developing a...read more